Grn163l

Grn163l Uses, Dosage, Side Effects, Food Interaction and all others data.

GRN163L is a novel anti-cancer drug. It has been characterized preclinically and shown to inhibit telomerase in human tumor cells of many cancer types (including lung, breast, prostate, liver, and early stage of human breast cancer), in both cell culture systems and animal models. Study of this drug shows the its potential utility in the treatment of patients with hematologic and solid tumor malignancies.

Trade Name Grn163l
Generic Grn163l
Type
Groups Investigational
Therapeutic Class
Manufacturer
Available Country
Last Updated: September 19, 2023 at 7:00 am
Grn163l
Grn163l

Uses

Investigated for use/treatment in leukemia (lymphoid) and solid tumors.

How Grn163l works

GRN163L has been characterized preclinically and shown to inhibit telomerase in human tumor cells of many cancer types. It targets the template region, or active site, of telomerase. GRN163L does not exhibit antisense activity (binding to messenger RNA), but rather directly bind to the RNA component of telomerase at the active site of the enzyme, thereby acting like a conventional pharmaceutical drug. Inhibiting telomerase activity should result in telomere shortening and therefore cause aging and death of cancer cells.

Innovators Monograph

You find simplified version here Grn163l

*** Taking medicines without doctor's advice can cause long-term problems.
Share